SCHEMBL506128

SCHEMBL506128

CC(N)C1CNCCN1CCN

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.42
DPP4 P27487 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10385183 0.85 TDP1 (0.41) TDP1DPP4DPP7
SCHEMBL10385673 0.85 TDP1 (0.39) TDP1DPP4DPP7
SCHEMBL6700157 0.82 TDP1 (0.40) TDP1
SCHEMBL2923096 0.81 TDP1 (0.41) TDP1
SCHEMBL1263683 0.77 TDP1 (0.33) TDP1
SCHEMBL10785211 0.77 TDP1 (0.35) TDP1
SCHEMBL782155 0.76 TDP1 (0.32) TDP1DPP4DPP7
SCHEMBL2764648 0.76 DPP4 (0.36) TDP1DPP4DPP7
SCHEMBL10380239 0.75 CYP2D6 (0.37) TDP1
SCHEMBL5474455 0.74 TDP1 (0.34) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
US-20200148647-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2020-05-14 US disclosed
US-20170226064-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2017-08-10 US disclosed
US-9556123-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2017-01-31 US disclosed
US-20160102060-A1 Synthesis of Triethylenetetramines PROTEMIX CORPORATION LIMITED (NZ) 2016-04-14 US disclosed
US-20150057466-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2015-02-26 US disclosed
US-8912362-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2014-12-16 US disclosed
US-20130345311-A1 Synthesis Of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2013-12-26 US disclosed
EP-1778618-B1 SYNTHESIS OF TRIETHYLENETETRAMINES PHILERA NEW ZEALAND LTD (NZ) 2013-12-25 EP disclosed
US-8394992-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2013-03-12 US disclosed
US-20120029203-A1 Synthesis Of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2012-02-02 US disclosed
US-8067641-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2011-11-29 US disclosed
US-20100173994-A1 Synthesis of triethylenetetramines PROTEMIX CORPORATION LIMITED (NZ) 2010-07-08 US disclosed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US disclosed
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PHILERA NEW ZEALAND LIMITED (NZ) 2006-02-23 US disclosed
US-4946612-A Lubricating oil composition for sliding surface and for metallic working and method for lubrication of machine tools using said composition IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795150-B2 Synthesis of triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20160102060-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20170226064-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20130345311-A1 Synthesis Of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20120029203-A1 Synthesis Of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20150057466-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20200148647-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride TET1, TET2, TET3 TDP1 600/4885DPP4 3945/4885DPP7 3859/4885
US-20100173994-A1 Synthesis of triethylenetetramines PNMT, TES, TPR TDP1 1337/4885DPP4 4334/4885DPP7 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.